Full Press Release Details
Data Published In Nature Communications Demonstrates CoA Therapeutics' Potential To Treat Genetically Driven Pantothenate Kinase-associated Neurodegeneration (PKAN).
BBIO
Data Published In Nature Communications Demonstrates CoA Therapeutics' Potential To Treat Genetically Driven Pantothenate Kinase-associated Neurodegeneration (PKAN)
Key Takeaway: Data Published In Nature Communications Demonstrates CoA Therapeutics' Potential To Treat Genetically Driven Pantothenate Kinase-associated Neurodegeneration (PKAN)
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis